Abstract
In vivo administration of the phenothiazine drug, thioridazine, inhibits hepatic peroxisomal beta-oxidation in mice. In starving animals, 3-hydroxybutyrate concentration is not decreased by thioridazine treatment. These results provide the first demonstration of thioridazine as a selective inhibitor of peroxisomal beta-oxidation in intact animals. Thioridazine might supply a tool for simulation of pathological conditions in which peroxisomal beta-oxidation is impaired.
| Original language | English |
|---|---|
| Pages (from-to) | 331-333 |
| Number of pages | 3 |
| Journal | FEBS Letters |
| Volume | 187 |
| Publication status | Published - 1985 |